128 related articles for article (PubMed ID: 37169262)
21. Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma.
van Beek JGM; Ramdas WD; Angi M; van Rij CM; Naus NC; Kacperek A; Errington RD; Damato B; Heimann H; Kiliç E
Radiother Oncol; 2021 Apr; 157():219-224. PubMed ID: 33549643
[TBL] [Abstract][Full Text] [Related]
22. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
[TBL] [Abstract][Full Text] [Related]
23. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
[TBL] [Abstract][Full Text] [Related]
24. Proton beam therapy and iris neovascularisation in uveal melanoma.
Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA
Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
[TBL] [Abstract][Full Text] [Related]
25. Diffuse iris melanoma: a report of 25 cases.
Demirci H; Shields CL; Shields JA; Eagle RC; Honavar SG
Ophthalmology; 2002 Aug; 109(8):1553-60. PubMed ID: 12153810
[TBL] [Abstract][Full Text] [Related]
26. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.
Wuestemeyer H; Sauerwein W; Meller D; Chauvel P; Schueler A; Steuhl KP; Bornfeld N; Anastassiou G
Graefes Arch Clin Exp Ophthalmol; 2006 Apr; 244(4):438-46. PubMed ID: 16133022
[TBL] [Abstract][Full Text] [Related]
27. Iris melanoma outcomes based on the Cancer Genome Atlas (TCGA) classification in 78 consecutive patients.
Cherkas E; Negretti GS; Zeiger JS; Shields CL
Ophthalmic Genet; 2022 Dec; 43(6):736-741. PubMed ID: 36326016
[TBL] [Abstract][Full Text] [Related]
28. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
29. Visual improvement after cultivated oral mucosal epithelial transplantation.
Sotozono C; Inatomi T; Nakamura T; Koizumi N; Yokoi N; Ueta M; Matsuyama K; Miyakoda K; Kaneda H; Fukushima M; Kinoshita S
Ophthalmology; 2013 Jan; 120(1):193-200. PubMed ID: 23084239
[TBL] [Abstract][Full Text] [Related]
30. Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy.
Shields CL; Shields JA; De Potter P; Singh AD; Hernandez C; Brady LW
Br J Ophthalmol; 1995 Apr; 79(4):306-12. PubMed ID: 7742272
[TBL] [Abstract][Full Text] [Related]
31. Conservative management of suspicious melanocytic lesions of the iris.
Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma.
Xu TT; Pulido JS; Deufel CL; Corbin KS; Petersen IA; Dalvin LA
Eye (Lond); 2021 Oct; 35(10):2754-2762. PubMed ID: 33235338
[TBL] [Abstract][Full Text] [Related]
33. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study.
Khan S; Finger PT; Yu GP; Razzaq L; Jager MJ; de Keizer RJ; Sandkull P; Seregard S; Gologorsky D; Schefler AC; Murray TG; Kivelä T; Giuliari GP; McGowan H; Simpson ER; Corriveau C; Coupland SE; Damato BE
Arch Ophthalmol; 2012 Jan; 130(1):57-64. PubMed ID: 21911649
[TBL] [Abstract][Full Text] [Related]
35. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
36. Plaque radiation therapy for malignant melanoma of the iris and ciliary body.
Finger PT
Am J Ophthalmol; 2001 Sep; 132(3):328-35. PubMed ID: 11530044
[TBL] [Abstract][Full Text] [Related]
37. Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates.
van Beek JGM; van Rij CM; Baart SJ; Yavuzyigitoglu S; Bergmann MJ; Paridaens D; Naus NC; Kiliç E
Acta Ophthalmol; 2022 Aug; 100(5):511-519. PubMed ID: 34529346
[TBL] [Abstract][Full Text] [Related]
38. Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre.
Shukla AG; Vaidya S; Yaghy A; Di Nicola M; Kaliki S; Fulco E; Myers JS; Shields JA; Shields CL
Eye (Lond); 2023 Apr; 37(5):938-946. PubMed ID: 35383310
[TBL] [Abstract][Full Text] [Related]
39. Management of iris melanomas with 125Iodine plaque radiotherapy.
Fernandes BF; Krema H; Fulda E; Pavlin CJ; Payne DG; McGowan HD; Simpson ER
Am J Ophthalmol; 2010 Jan; 149(1):70-6. PubMed ID: 19892312
[TBL] [Abstract][Full Text] [Related]
40. Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy.
Konstantinidis L; Groenewald C; Coupland SE; Damato B
Br J Ophthalmol; 2014 Jun; 98(6):775-9. PubMed ID: 24568869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
